Metabolomics Biomarker Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 3.30 Bn

Forecast Year, 2035

USD 10.85 Bn

CAGR, 2026 - 2035

12.64%

Report Coverage

Global

What is the Metabolomics Biomarker Market Size in 2026?

The global metabolomics biomarker market size was calculated at USD 3.30 billion in 2025 and is predicted to increase from USD 3.72 billion in 2026 to approximately USD 10.85 billion by 2035, expanding at a CAGR of 12.64% from 2026 to 2035. The market is driven by rising chronic diseases and demand for precision medicine. The increasing use of metabolomics biomarkers as diagnostics and research applications fosters market growth.

Key Takeaways

• North America held a dominant revenue share of the market in 2025.
• Asia-Pacific is expected to expand at the fastest CAGR in the market between 2026 and 2035.
• By type, the targeted metabolomics segment dominated the market in 2025.
• By type, the untargeted metabolomics segment is expected to grow at a strong CAGR during 2026 and 2035.
• By application, the drug discovery segment captured the largest market share in 2025.
• By application, the personalized medicine segment is expected to expand at the fastest CAGR from 2026 to 2035.

Is the Metabolomics Biomarker Market Changing Diagnostic Precision?

The market encompasses the identification, validation, and commercialization of small molecule metabolites as measurable indicators of physiological and/or pathological states, i.e., an aid to disease detection, therapeutic monitoring, and drug development. The market growth can be attributed to the fact that healthcare systems worldwide are placing an increased emphasis on precision medicine and early-stage diagnosis. The introduction of new methods of analysis, including high-throughput methods of analysis and increased sensitivity and reproducibility, has improved the ability of laboratories to perform metabolic profiling on a larger scale than ever before.

Pharma companies have also begun to introduce the use of metabolomics biomarkers into their clinical trial designs to stratify patient populations and predict drug responses. The increasing prevalence of cancer, metabolic disorders, and conditions associated with neurodegenerative disease continues to provide for increased market demand. Additionally, by partnering with academic institutions and biotechnology companies, they are accelerating translational research that makes metabolomics biomarkers a critical component of next-generation diagnostic and therapeutic modalities.

How AI Drives Next-Generation Metabolomics Biomarker Market?

Artificial intelligence is transforming the metabolomics biomarker industry by enhancing the speed, accuracy, and value of analytics. AI algorithms provide large volumes of data interpretation, which allows companies to quickly identify disease-specific metabolic markers and accelerate biomarker discovery. This gives companies a significant advantage for precision diagnostics and drug development. The fusion of AI with metabolomics also reduces research and development timelines and costs, enabling companies to differentiate themselves more from their competitors in the biotechnology and contract research organization (CRO) industry.

• For instance, In January 2026, BioMark Diagnostics, a leading company that validated machine learning derived metabolomic models used for the detection of early-stage lung cancer, announced long-term investment in integrating AI and machine learning into metabolomic profiling.

In addition, platforms that integrate AI with multi-omics capabilities are gaining traction and expanding the overall market potential of metabolomics beyond traditional metabolomic workflows. Collectively, these trends illustrate that AI will continue to drive innovation, attract funding, and accelerate commercialization in both diagnostic and therapeutic markets.

Key Trends Driving the Metabolomics Biomarker Market

• Precision-Based Diagnostics: There is a rising interest in using metabolomics biomarkers for the early detection of diseases, as well as stratifying patients and monitoring their responses to different therapies, especially within oncology, metabolic diseases, and neurological issues.
• Integration of AI: Through the use of AI and ML technologies, the processing of metabolic data is being enhanced through advanced methods of identifying more complicated signatures associated with metabolic activity, resulting in improved efficiencies in terms of speed, predictive accuracy, and clinical translations related to the discovery of novel biomarkers.
• The Multi-Omics Effect: The convergence of metabolomics, genomics, proteomics, and transcriptomic research is providing the possibility of obtaining a more comprehensive understanding of biological processes, resulting in advances in systems biology and a greater degree of rigor in biomarker validation across all therapeutic classes.
• Clinical Translation: An increase in the number of collaboration agreements between research institutions, biotechnology companies, and pharmaceutical companies is resulting in the commercialization of metabolomics-based assays, with an increasing level of regulatory scrutiny around the validation, reproducibility, and clinical utility of these assays.

Market Scope

Segmental Insights

Type Insights

Why Did the Targeted Metabolomics Segment Lead the Metabolomics Biomarker Market?

The targeted metabolomics segment led the market in 2025, because of its significant high fidelity, reproducibility, and clinical usability. Targeted metabolomics is primarily used to measure pre-established metabolites and is ideal for regulated environments like drug development and scheduled clinical validation studies.

Given the fact that targeted metabolomics is so widely accepted in validating and executing biomarker analysis studies and conducting therapeutic monitoring studies, it contributes significantly to ongoing revenue, particularly in drug development and translational research.

The untargeted metabolomics segment is expected to expand rapidly in the market during the forecast period, due to the increasing demand from researchers for comprehensive and global metabolic profiling to discover new biomarkers. Untargeted metabolomics allows researchers to perform simultaneous analysis of numerous metabolites, which is ideal for exploratory studies related to complex diseases. Additional investments in cutting-edge mass spectrometry and data analytics platforms are leading to greater use of untargeted metabolomics for early drug development efforts and in systems biology applications.

Application Insights

Which Application Segment Dominated the Metabolomics Biomarker Market?

The drug discovery segment held a dominant position in the market in 2025 because more companies are focusing on accurately identifying biomarkers during target validation and toxicity determination. Metabolomics provides a better understanding of disease pathways and responses to drugs, allowing pharmaceutical companies the ability to better optimize their selection of candidates. Through metabolomics, preclinical and clinical development pipelines increase efficiency and decrease the number of projects failing in late-stage development, further solidifying metabolomics' place in the market.

The personalized medicine segment is expected to grow with the highest CAGR in the market during the studied years, as physicians are changing how they treat patients. Metabolomic biomarkers allow physicians to make treatment decisions based on their patients' unique metabolomic profiles. With the recent rise in interest in precision-based health care systems and better-developed data-driven diagnostic tools, metabolomics will continue to expand for the purpose of treating cancer patients and individuals suffering from metabolic or rare diseases.

Regional Insights

Why North America Dominated the Metabolomics Biomarker Market?

North America held a major revenue share of the market in 2025, as the region is fully equipped with a functional healthcare system. This facilitates the metabolomics biomarkers industry to develop a robust and effective platform for implementing metabolomics as an integral part of clinical and pharmaceutical research. Major research institutions and biotechnology clusters across North America (U.S. & Canada) are utilizing metabolite profiling to enable the early identification of disease markers and support precision medicine. The advent of new multi-omic data analytics platforms, supported by regulatory agencies and public research funders, will enable North America to be the premier region in the world for the clinical translation of metabolomics into actionable biomarkers.

U.S. Market Trends

The U.S. leads globally in metabolomics biomarker development due to its strong investment in biomedical research funding, its density of biotech start-ups, and extensive clinical research initiatives. Advanced mass spectrometry methods are being developed in U.S. laboratories, using ML or AI to interpret data, identify a variety of metabolic profiles associated with cancers and type 2 diabetes, and the ongoing cooperation between academia and industry continues to enhance the practical application of disease discovery through the support of funding.

Why is Asia-Pacific Experiencing Fastest Growth in the Metabolomics Biomarker Market?

Asia-Pacific is expected to grow at the fastest CAGR in the market during the forecast period, with the continual investment/dedication by the government and private sectors into healthcare systems, including the heavy burden of chronic disease and the expansion of existing research capabilities across countries like China, Japan, and India.

It becomes evident that this region has developed into a focal point for the development and use of metabolomic biomarkers. Federal and state government agencies, as well as various private entities, are investing billions of dollars into developing the necessary life sciences infrastructure to support metabolite profiling and biomarker discovery. This will provide the vehicle for many early diagnostics and personalized medicine.

Furthermore, the diversity and multitude of the population in this region will allow for extensive clinical research and the implementation of clinical applications. New timeframes and regulatory changes across many of the Asia-Pacific markets will facilitate the development of metabolomics and other forms of omics research into the healthcare and pharmaceutical development pipeline. In addition, this region will be positioned as a key global market for innovative and cutting-edge metabolic biomarker research and development.

China Market Trends

China is positioned as a leader within the region. The Chinese government has initiated many programs directed towards facilitating the development of research within the metabolomics area by strategically funding various omics programs and by significantly investing in modern laboratory infrastructure.

Additionally, many Chinese research institutions are participating in collaborations with institutions from other parts of the globe, and this expanded reach will allow Chinese researchers to perform large-scale, high-throughput analyses using metabolic profiling technologies to respond to the major issues of public health and to establish the nation as a key global player in the area of metabolic biomarker innovation.

Will Europe Grow in the Metabolomics Biomarker Market?

Europe is expected to grow at a notable CAGR in the foreseeable future. The market growth is driven by advances in genomic technologies, growing research and development activities, and favorable government support. People are becoming increasingly aware of screening and early diagnosis of chronic disorders, such as cancer and diabetes, potentiating the demand for metabolomics biomarkers. The increasing public-private partnership and rising R&D investments propel the market. The rapidly expanding healthcare infrastructure through collaborations with intergovernmental organizations also contributes to market growth.

UK Market Trends

The UK is at the forefront of advancing genomics research and developing personalized medicines through extensive clinical research. The UK government is making constant efforts to make the region a global hub in clinical trials. As of 28th February 2026, there were 28 clinical trials registered on the clinicaltrials.gov website related to personalized medicines in the UK. The recent release of the UK Biobank's metabolomics dataset of 500K profiles further amplifies market growth.

Metabolomics Biomarker Market Value Chain Analysis

Metabolomics Biomarker Market Companies

• Agilent Technologies
• Thermo Fisher Scientific
• Bruker Corporation
• Waters Corporation
• Shimadzu Corporation
• Danaher Corporation
• PerkinElmer
• Bio-Rad Laboratories
• Metabolon Inc.
• Biocrates Life Sciences AG
• Human Metabolome Technologies
• LECO Corporation
• NMR Metabolomics
• Chenomx Inc.
• Creative Proteomics
• Metabolomic Discoveries
• Biomark Diagnostics Inc.
• Metabolomics Australia
• Metabolomic Technologies Inc.
• Cayman Chemical Company

Segments Covered in the Report

By Type

• Targeted Metabolomics
• Untargeted Metabolomics

By Application

• Drug Discovery
• Nutrigenomics
• Personalized Medicine
• Clinical Diagnostics
• Toxicology Testing

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa